Clifford Chance
Clifford Chance advises on proposed take-private of Kangji Medical by TPG-led consortium
25 August 2025
- Alex Bidlake, Chloe Choy, Liyong Xing, Michael Pallaras, Priscilla Au-Yeung, Adam Boulanger, Kin Kan Chan, Jia Yin Leong
- Hong Kong
Clifford Chance advises on proposed take-private of Kangji Medical by TPG-led consortium
Global law firm Clifford Chance is advising J.P. Morgan in its role as exclusive financial advisor on the proposed take-private of Hong Kong-listed Kangji Medical by a consortium led by TPG, Qatar Investment Authority (QIA) and Kangji Medical's co-founders Mr. Zhong Ming and Ms. Shentu Yinguang. The proposal values Kangji Medical at US$1.4 billion.
This transaction is one of the largest private equity-led take-private transactions in Asia this year and underscores continued investor interest in China's healthcare sector. Hangzhou-based Kangji Medical is a leading Chinese medical device manufacturer which designs and manufactures minimally invasive surgical instruments.
The Clifford Chance team is led by M&A partner Alex Bidlake and counsel Chloe Choy, with support from partners Liyong Xing and Michael Pallaras, senior associate Jia Yin Leong, associates Priscilla Au-Yeung, Adam Boulanger and Kin Kan Chan.
This transaction builds on Clifford Chance’s strong track record advising on high-profile take-private transactions, having recently advised on the privatisations of ENN Energy, Beijing Capital Grand Limited and L'Occitane International.
高伟绅就TPG牵头财团拟议私有化康基医疗项目提供法律服务
国际领先律师事务所高伟绅在由TPG、卡塔尔投资局(QIA)及香港上市公司康基医疗控股有限公司（“康基医疗”）联合创始人钟鸣先生和申屠银光女士组成的财团对康基医疗的拟议私有化项目中，为独家财务顾问摩根大通提供法律服务。本次私有化项目对康基医疗的估值达14亿美元。
该交易系亚洲市场本年度规模最大的由私募基金主导的私有化交易之一，凸显国际投资者对中国医疗健康领域的持续关注。康基医疗总部位于杭州，是一家领先的中国医疗器械制造商，专注于微创外科手术医疗器械的研发及生产。
高伟绅律师团队由并购业务合伙人Alex Bidlake及资深顾问律师蔡旻昉(Chole Choy)牵头领导，并由合伙人邢丽咏和Michael Pallaras，欧阳沛琳(Priscilla Au-Yeung)、Adam Boulanger、陈健勤(Kin Kan Chan)及梁嘉茵(Jia Yin Leong)提供协助。
